



## ASX Announcement


04 December 2017

**Creso Pharma signs exclusive commercialization agreement with the Swiss Pharma company Doetsch Grether for marketing and distributing Creso's cannaQIX®10 in Switzerland setting the cornerstone for Creso's global commercialization**

### Highlights:

- **Creso Pharma has obtained the necessary approvals to market its hemp based nutraceutical cannaQIX®10 in Switzerland as a Food Supplement compliant with Swiss Federal food law;**
- **Creso Pharma and Doetsch Grether signed an exclusive commercialization agreement to market and launch Creso's hemp based cannaQIX®10 product in Switzerland through Doetsch Grether's distribution channels;**
- **This strategic commercial partnership and cannaQIX®10 launch in Switzerland sets the cornerstone for Creso Pharma's global commercialization strategy using Switzerland as a reference country.**

**Creso Pharma Limited** (ASX:CPH, the "Company" or "Creso") is pleased to announce that it has obtained the confirmation of compliance with the Swiss Federal Food law to market its first hemp based nutraceutical cannaQIX®10 as a Food Supplement, and signed an exclusive commercialization agreement with the highly reputed traditional Swiss Pharma company Doetsch Grether for the marketing and distribution in Switzerland and Liechtenstein.





The agreement between Creso Pharma and Doetsch Grether covers the exclusive marketing and distribution of cannaQIX®10 in the Swiss market for 10 years targeting the biggest pharmacy and drug store chains in both Switzerland and Lichtenstein (European country).

Doetsch Grether is one of the largest Pharma /OTC & Consumer Care companies in Switzerland. It is a medium-sized, family-owned company with traditional values specialized in the marketing and distribution of products in the pharma, OTC and consumer care Swiss market and been operating since 1899.

Doetsch Grether's portfolio consists of their own brands, such as their famous Grether's Pastilles, as well as distribution brands which it's marketing with sales team support throughout Switzerland.



The marketing and distribution of OTC products and food supplement products such as cannaQIX®10 require a listing into the pharmacy and drug store chains, which are supplied through wholesalers. Creso's exclusive agreement with Doetsch Grether means that the Company will have access to over 2,300 outlets throughout Switzerland and Lichtenstein. The launch of cannaQIX®10 product remains in the planning stages with implementation starting, March 2018.

Dr. Miri Halperin Wernli, CEO and Co-Founder of Creso Pharma said: "We are proud for having achieved a further milestone obtaining the marketing approval for cannaQIX®10 in Switzerland and we are delighted to enter Creso's home market, Switzerland, with Doetsch Grether allowing us to launch and market cannaQIX®10 throughout pharmacy and drug store chains in Switzerland and Lichtenstein.

Thomas Wyss, CEO of Doetsch Grether Ltd.: "We see strong demand in safe and reliable Hemp-derived products in the Swiss market. The cooperation with Creso Pharma gives us the great opportunity to bring a unique and attractive Hemp-derived nutraceutical first to the Swiss pharmacies and drugstores."



## cannaQIX®10

cannaQIX®10 is a hemp-based nutraceutical in Creso's proprietary innovative delivery technology. The pharma-grade, CBD-based product comes in packs of 20, 40 and 60 pastilles.



The pastille, which is a delivery formulation designed for buccal absorption, works faster and more efficiently than tablets or capsules that need to be swallowed. Tablets and Capsules have a high percentage of their ingredients broken down when absorbed through the intestine and passed through the liver whereas the cannaQIX pastille is formulated to dissolve in the mouth with the active ingredients entering the blood stream directly making the delivery much faster and dose complete.

cannaQIX®10 is standardized in dose and formulation with unique composition designed to provide support during stress and anxiety conditions for our patients/consumers.

cannaQIX®10 has been developed to the highest Swiss standards and is produced in Switzerland by Creso's partner Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality and will be released with the much sought after "Swiss Made" label.

With cannaQIX®10 Creso offers a safe and effective certified Food Supplement with broad access without the need for medical prescriptions.

The target CBD addressable market with cannaQIX® 10 in Switzerland is estimated at CHF 30-40 million in 2022 (~AUD 40-52 million).

The introduction of cannaQIX®10 into the Swiss market is the gateway for further global launches. Switzerland will be used as an international regulatory, quality and market reference country.



## **Appointment of new Finance Director**

The Company is pleased to announce the appointment of Mr Chris Grundy who has joined Creso as Head of Finance and will be based in our Sydney office. Mr Grundy is an accomplished, versatile, big-4 qualified, commercial CFO and Company Secretary with broad experience in private, public and listed SMEs including Private Equity investees. He has over 25 years' of finance experience both here in Australia and internationally. His experience includes working with pharmaceutical, medical device, hospitals, medical services and education businesses.

The board of Creso Pharma is very happy with this appointment and Creso's CEO and Co-Founder, Dr Halperin Wernli said: "We are delighted to have an executive of Chris's calibre with his impressive track record and solid financial experience, join the Creso team. His career brings the required skill set to help Creso develop solid multi-currency financial models and more stringent internal controls during this time of incredible growth".

Furthermore, Mr David Russell will be leaving the Company. David was working in a contractor capacity as COO over the last eight months and leaves Creso to go back to his independent consultancy. Creso thanks David for his contribution over the last eight months and wishes him all the best for his future business endeavours. Creso will look to replace his role with a more expanded position for the Australian office in due course.

### **About Creso Pharma**

[www.cresopharma.com](http://www.cresopharma.com)

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medicinal cannabis and strives for the highest quality in its products. It is the leader in medicinal cannabis and cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade nutraceuticals and medicinal cannabis products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Creso Pharma Switzerland develops, produces and markets worldwide hemp-based innovative nutraceutical products for humans and complementary feed products for animals. In Switzerland, Creso Pharma Switzerland markets its human nutraceuticals with commercial partners in the several countries

### **About Doetsch Grether**

[www.doetschgrether.ch](http://www.doetschgrether.ch)

Doetsch Grether is one of the largest Pharma /OTC & Consumer Care company in Switzerland. It is a medium-sized, family-owned company with traditional values specialised in the marketing and distribution of products in the pharma, OTC and consumer care in the Swiss market, privately owned and on the market since 1899.

Doetsch Grether's portfolio consists of their own brands, such as their famous Grether's Pastilles, and distribution brands which their marketing and sales team support throughout Switzerland.

### **About Domaco, Dr. med Aufdermaur AG**

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimize their absorption.

-ENDS-



**Investor Enquiries:**

Gabriella Hold  
M: 0411 364 382  
E: [gabriella.hold@mcpartners.com.au](mailto:gabriella.hold@mcpartners.com.au)

**Media Enquiries:**

Elise Hughan  
M: 0458 855 500  
E: [elise.hughan@mcpartners.com.au](mailto:elise.hughan@mcpartners.com.au)

**Corporate Queries:**

EverBlu Capital  
Level 39, Aurora Place  
88 Phillip Street, Sydney, NSW 2000  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000